Version history

{
  "description": "While the authors reference safety data from ruxolitinib trials, the efficacy of baricitinib for reversing cognitive deficits in human HAND patients remains untested. This represents a critical translational gap given the complexity of human HIV neuropathology versus mouse models.\n\nGap type: open_question\nSource paper: Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. (2019, Journal of neuroinflammation, PMID:31561750)",
  "domain": "neuroinflammation",
  "status": "open",
  "priority_score": 0.87,
  "importance_score": 0.9,
  "tractability_score": 0.85,
  "source": "pubmed:31561750",
  "resolution_criteria": "Resolution requires: (1) head-to-head comparison of JAK inhibitors (tofacitinib, baricitinib) vs vehicle in HAND mouse model (HIV-1 transgenic or infected mice) measuring cognitive outcomes (Morris water maze, operant conditioning) and viral load; (2) demonstration that JAK inhibition reduces neuroinflammation (Iba1, CD68, cytokines) and improves synaptic markers (synaptophysin, PSD95); (3) PK study establishing brain penetration at effective doses. Mouse behavioral improvement without mechanistic understanding is insufficient.",
  "market_price": 0.5
}